Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.65
Bid: 37.20
Ask: 37.50
Change: -0.125 (-0.33%)
Spread: 0.30 (0.806%)
Open: 37.30
High: 37.65
Low: 37.00
Prev. Close: 37.475
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licenses CSD500 to Church & Dwight

2 Apr 2013 07:00

RNS Number : 2832B
Futura Medical PLC
02 April 2013
 



For immediate release

2 April 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

 

Futura licenses CSD500 to Church & Dwight

 

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has signed a licensing deal with Church & Dwight Co Inc, the major US consumer products group whose brands include Trojan® condoms, for the marketing and distribution of CSD500, Futura's novel condom.

 

Trojan® is the number one condom brand in North America and the world's second biggest condom brand by product sales.

 

Under the terms of the agreement, Church & Dwight will hold the rights to manufacture, market and distribute CSD500 in North America and in a number of key European territories.

 

The financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Adrian Huns, Church & Dwight's President of International Consumer Products, commented: "CSD500 is a genuinely novel condom that marks a major breakthrough in condom technology. We look forward to working with Futura on the successful completion of the required approvals necessary ahead of the launch in Europe and North America of a completely new type of condom from a highly trusted brand."

 

James Barder, Futura's Chief Executive, commented: "We are delighted to sign this pivotal agreement with Church & Dwight for the marketing of CSD500 as a Trojan®-branded condom in North America and in key territories in Europe. Trojan® is one of the world's biggest condom brands and the number one brand in North America."

 

"The agreement is in line with the Board's preferred strategy of licensing CSD500 on a geographic basis to condom distributors that hold leading positions in their regions. We continue to negotiate CSD500 rights for other major territories and believe that this strategy will create optimal value for shareholders."

 

 

For further information:

 

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKBDQPBKKNQK
Date   Source Headline
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares
10th Sep 20157:00 amRNSGrant of Options
9th Sep 20157:00 amRNSInterim Results
19th Aug 20153:15 pmRNSNotification of Major Interest in Shares
19th Aug 20157:00 amRNSNotice of Interim Results
16th Jul 20154:23 pmRNSNotification of Major Interest in Shares
14th Jul 20157:00 amRNSHeadline Results from Pain Relief Study
13th Jul 20157:00 amRNSNotice of Pain Relief Portfolio Study Results
25th Jun 20157:00 amRNSCommencement of MED2002 Clinical Trial
17th Jun 20155:45 pmRNSResult of AGM
17th Jun 20157:00 amRNSAGM Statement
3rd Jun 20155:20 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20157:00 amRNSPain Relief Portfolio: Study Update
11th May 20157:00 amRNSBlock Listing Update
11th May 20157:00 amRNSBlue Diamond® Retail Roll-out
24th Apr 20153:00 pmRNSNotice of AGM
31st Mar 20155:05 pmRNSNotification of Major Interest in Shares
25th Mar 20157:00 amRNSPreliminary Results
18th Mar 20157:00 amRNSPain Relief Portfolio Study Commences
16th Mar 20155:48 pmRNSAIM Disclosure
3rd Mar 20154:52 pmRNSNotification of Major Interest in Shares
5th Feb 20157:00 amRNSUS Patent Extension for MED2002
2nd Feb 20151:18 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
28th Jan 20151:10 pmRNSNotification of Major Interest in Shares
23rd Jan 201510:14 amRNSNotification of Major Interest in Shares
22nd Jan 20152:33 pmRNSDirector Shareholding
15th Jan 201512:32 pmRNSNotification of Major Interest in Shares
15th Jan 201512:14 pmRNSDirector's Dealings
15th Jan 20157:00 amRNSNotice of Preliminary Results
5th Jan 20157:00 amRNSRemuneration of Non-Executive Directors
15th Dec 20147:00 amRNSAppointment of CRO for MED2002 Clinical Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.